Emergent BioSolutions appointed Joseph C. Papa as President and CEO

Papa will lead Emergent into a new era of focusing on protecting public health

Emergent BioSolutions Inc. (NYSE: EBS), a global company specializing in addressing public health threats and bringing life-extending products to market, has announced the appointment of Joseph C. Papa as president and CEO, effective February 21, 2024. Mr. Papa will succeed Haywood Miller, who will step down from his role as interim CEO on the same date. Zsolt Harsanyi, Ph.D., chairman of the Board of Directors, expressed satisfaction with the appointment, stating that Joe Papa brings extensive experience in the pharmaceutical and healthcare industries, along with a proven track record of driving growth and managing transformative periods for companies. The Board acknowledges Mr. Miller's leadership and contributions during the interim period.

Mr. Papa emphasized Emergent's role in addressing global health crises through critical products such as NARCAN® Nasal Spray and medical countermeasures. He expressed confidence in the company's future and its ability to lead in public health preparedness. Mr. Miller, reflecting on his time leading Emergent, expressed optimism about the company's financial foundation and core products business, affirming its position as a global leader in preparedness and public health. Looking ahead, Mr. Papa expressed his eagerness to collaborate with the team to accelerate Emergent's progress, enhance its financial position, and drive value for shareholders. He sees joining Emergent as a privilege and an opportunity to chart a new chapter in the vital public health space.